Major inclusion criteria were

- Ethics committees from all participating centers. A signed consent form was obtained and patients gave their consent to participate in the study. The study was approved by the regulatory authorities and was performed according to the Declaration of Helsinki and Good Clinical Practice guidelines.

- The study hypothesis is that dual blockade, in patients with HR+, HER2+ metastatic or locally advanced MBC, could increase activity among HER2+/HR+ patients.

- Lapatinib plus trastuzumab treatment-related toxicities did not condition CBR, TTP and OS.

- The median time to progression (TTP) was 3.9 months (95% CI: 2.8-5.0 months). The Overall Response Rate (ORR) was 24 weeks (Table 2).

- The Overall Response Rate (ORR) was 24 weeks (Table 2).

- Higher TTP (p=0.011), significant trend) was observed in patients with prior exposure to trastuzumab for more than one prior line of chemotherapy and/or prior exposure to trastuzumab for more than one prior line of trastuzumab.

- The median age (years) of the total sample was 58 (IQR: 55-62)

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62). The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).

- The median age (years) of the total sample was 58 (IQR: 55-62).